Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 584,376,384
  • Shares Outstanding, K 2,409,899
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 30,550 M
  • EBITDA $ 38,053 M
  • 60-Month Beta 0.35
  • Price/Sales 6.32
  • Price/Cash Flow 17.49
  • Price/Book 7.30

Options Overview Details

View History
  • Implied Volatility 21.89% (+0.97%)
  • Historical Volatility 15.29%
  • IV Percentile 90%
  • IV Rank 41.65%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 6) 4.51 (1.86%)
  • Put/Call Vol Ratio 0.31
  • Today's Volume 57,939
  • Volume Avg (30-Day) 27,265
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 417,287
  • Open Int (30-Day) 364,509
  • Expected Range 237.98 to 247.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.68
  • Number of Estimates 8
  • High Estimate 2.85
  • Low Estimate 2.41
  • Prior Year 2.77
  • Growth Rate Est. (year over year) -3.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
210.50 +15.20%
on 01/21/26
246.96 -1.81%
on 02/19/26
+24.28 (+11.13%)
since 01/20/26
3-Month
199.90 +21.30%
on 12/09/25
246.96 -1.81%
on 02/19/26
+39.42 (+19.41%)
since 11/20/25
52-Week
141.50 +71.37%
on 04/09/25
246.96 -1.81%
on 02/19/26
+82.81 (+51.86%)
since 02/20/25

Most Recent Stories

More News
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

More than 80% of those treated with TREMFYA ® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease...

JNJ : 242.49 (-1.79%)
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™ ; results surpass current standards of care

JNJ : 242.49 (-1.79%)
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Advanced manufacturing site will utilize cutting‑edge cell therapy technologies to help deliver the company’s portfolio of transformational medicines ...

JNJ : 242.49 (-1.79%)
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO ™ beyond lung cancer

JNJ : 242.49 (-1.79%)
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Monthly dosing reduces treatment visits while maintaining established safety and efficacy 1,2

JNJ : 242.49 (-1.79%)
Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Outcome marks the first of several trials scheduled for 2026

JNJ : 242.49 (-1.79%)
This New ETF Bolsters ‘America First’ Tech Stocks in Defiance of 'Sell America' Trade

As the "sell America" trade has gained popularity, the launch of USMD is doubling down on "America First" tech trades. Here's what to know.

MSFT : 397.23 (-0.31%)
GOOG : 314.90 (+3.74%)
GOOGL : 314.98 (+4.01%)
NVDA : 189.82 (+1.02%)
USMD : 25.14 (-0.23%)
AVGO : 332.65 (-0.40%)
TSLA : 411.82 (+0.03%)
CSCO : 79.20 (+0.81%)
JNJ : 242.49 (-1.79%)
AMD : 200.15 (-1.58%)
AMZN : 210.11 (+2.56%)
PLTR : 135.24 (+0.26%)
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

HELP : 6.81 (-1.30%)
AZN : 204.20 (-1.09%)
JNJ : 242.49 (-1.79%)
HELP.NE : 9.3500 (-1.58%)
ABBV : 224.81 (+0.21%)
TAK : 18.66 (unch)
Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28 th Annual Global Healthcare Conference on Tuesday, March 10 th , 2026. Management will participate in a Fireside...

JNJ : 242.49 (-1.79%)
5 Stocks and ETFs to Help Shield Your Portfolio During Volatility

Resilient stocks and ETFs offering steady demand and dividend yields may help investors weather further market turbulence without abandoning equity exposure.

XLV : 156.82 (-0.28%)
KO : 79.84 (+1.18%)
JNJ : 242.49 (-1.79%)
PG : 160.78 (+1.40%)
VYM : 155.56 (+0.23%)
IGV.BZ : N/A (N/A)
XLP : 87.89 (+0.25%)
WMT : 122.99 (-1.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 80%. The market has dropped from extreme overbought territory, indicating a possible trend reversal.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 252.75
2nd Resistance Point 249.82
1st Resistance Point 246.15
Last Price 242.49
1st Support Level 239.55
2nd Support Level 236.62
3rd Support Level 232.95

See More

52-Week High 246.96
Last Price 242.49
Fibonacci 61.8% 206.67
Fibonacci 50% 194.23
Fibonacci 38.2% 181.79
52-Week Low 141.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar